Evolus Inc
$ 4.49
-0.22%
26 Feb - close price
- Market Cap 291,689,000 USD
- Current Price $ 4.49
- High / Low $ 4.56 / 4.43
- Stock P/E N/A
- Book Value -0.44
- EPS -0.94
- Next Earning Report 2026-03-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.11 %
- ROE -187.30 %
- 52 Week High 14.94
- 52 Week Low 4.09
About
Evolus, Inc., a high-performance beauty company, provides aesthetic medical products for physicians and their patients in the United States. The company is headquartered in Newport Beach, California.
Analyst Target Price
$15.17
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-05 | 2025-05-05 | 2025-03-04 | 2024-11-06 | 2024-07-31 | 2024-05-07 | 2024-03-07 | 2023-11-07 | 2023-08-02 | 2023-05-09 | 2023-03-08 |
| Reported EPS | -0.24 | -0.27 | -0.17 | 0.0139 | -0.16 | -0.04 | -0.09 | -0.12 | -0.16 | -0.19 | -0.15 | -0.14 |
| Estimated EPS | -0.15 | -0.1 | -0.1 | 0.0223 | -0.1 | -0.05 | -0.1 | -0.07 | -0.17 | -0.19 | -0.15 | -0.15 |
| Surprise | -0.09 | -0.17 | -0.07 | -0.0084 | -0.06 | 0.01 | 0.01 | -0.05 | 0.01 | 0 | 0 | 0.01 |
| Surprise Percentage | -60% | -170% | -70% | -37.6682% | -60% | 20% | 10% | -71.4286% | 5.8824% | 0% | 0% | 6.6667% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-03 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.02 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EOLS
2026-02-25 12:52:44
Evolus, Inc. announced that its management team will participate in the Leerink Partners Global Healthcare Conference in Miami, FL. The team will engage in a fireside chat and investor meetings starting March 11, 2026, at 11:20 AM ET. A webcast of the fireside chat will be available on the Evolus Investor Relations page.
2026-02-25 12:52:44
Evolus, Inc. announced that its management team will participate in a fireside chat and investor meetings at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026, at 11:20 AM ET. The webcast of the fireside chat will be accessible on the Investor Relations page of the Evolus website, with a replay available for 90 days. Evolus is a global performance beauty company focusing on aesthetic injectables like Jeuveau and Evolysse.
2026-02-24 16:51:36
Evolus, Inc. (EOLS) is projected to report a significant year-over-year increase in earnings and higher revenues for the quarter ended December 2025, with results expected on March 3rd. Analysts anticipate quarterly earnings of $0.06 per share, a 500% rise, and revenues of $89.42 million, up 13.3%. Despite a positive Earnings ESP of +8.33%, the stock's Zacks Rank #4 suggests it's difficult to definitively predict an earnings beat.
2026-02-24 15:52:44
Evolus, Inc. (EOLS) is expected to report a significant year-over-year increase in earnings and higher revenues for the quarter ended December 2025, with results anticipated on March 3. The company has a positive Earnings ESP of +8.33%, indicating analysts are bullish, but a Zacks Rank of #4 makes a definitive earnings beat difficult to predict. Investors are advised to consider other factors alongside the Earnings ESP and Zacks Rank.
2026-02-20 20:50:24
The global botulinum toxins market is projected to reach USD 15.72 billion by 2030, growing at a CAGR of 12.0% from USD 8.92 billion in 2025, driven by increasing aesthetic consciousness and expanding therapeutic applications. Key players include AbbVie, Ipsen, and Galderma, with significant market share in North America, while the Asia Pacific region is expected to show the highest growth. The market is influenced by a shift towards minimally invasive procedures, biosimilar competition, and product innovation.
2026-02-17 21:57:27
Evolus, Inc. announced its plan to report fourth quarter and full-year 2025 financial results on Tuesday, March 3, 2026, after the U.S. financial markets close. The company will host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss these results, followed by a question-and-answer session. Details for participating in the call and accessing replays are provided.
